Midostaurin cut organ damage in systemic mastocytosis

Midostaurin completely resolved at least one type of organ damage for 45% of patients with advanced systemic mastocytosis, based on a multicenter, open-label, phase II, industry-sponsored trial. “Response rates were similar regardless of the subtype of advanced systemic mastocytosis, KIT mutation...
Source: Skin and Allergy News - Category: Dermatology Source Type: news